Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.012 | LONG TERM PATIENT SATISFACTION WITH COCHLEAR IMPLANTATION ELDERLY | Dr. Yu Ka Yin |
| 2010.484 | Comparison of the Hearing Performance between the Oticon Baha Ponto and a control Cochlear baha BP100 at CUHK in Hong Kong | Dr. Yu Ka Yin |
| 2026.473 | Quality Improvement Project on staff compliance with Physical Restraint Guidelines in an acute medical ward at Prince of Wales Hospital. | Ms. Yu Ka Yee |
| 2014.219 | Association between PM2.5 and lung function / Black Carbon exposure to concentration of exhaled NO in roadside newspaper vendors in Hong Kong | Mr. YU Ka Hei |
| 2017.407 | Protection against liver diseases by OGT-mediated autophagy |
Prof. YU Jun 于君 |
| 2015.648 | Elucidation of a novel tumor suppressor gene MAP9 in regulating chromosome instability in colon cancer |
Prof. YU Jun 于君 |
| 2015.171 | Functional characterization of squalene epoxidase in promoting fatty liver disease-associated liver cancer |
Prof. YU Jun 于君 |
| 2017.346 | Study on the association of the gut microbiota dysbiosis and colorectal cancer |
Dr. YU Jun 于君 |
| 2015.129 | A study of the clinical significance and molecular mechanism of FOXF2 as a tumor suppressor in gastric cancer/esophageal cancer | Dr. YU Jun |
| 2016.143 | Elucidation of a novel tumor suppressor gene tripartite motif 67 (TRIM67) in colorectal cancer |
Prof. YU Jun 于君 |
| 2017.157 | The role and clinical impact of SQLE in promoting non-alcoholic fatty liver disease through inducing intracellular cholesterol ester accumulation |
Prof. YU Jun 于君 |
| 2013.436 | Pathogenesis of non-alcoholic fatty liver disease: molecular basis and clinical application | Prof. YU JUN |
| 2014.177 | Functional characterization, clinical implication and targeted therapy of a newly discovered amplification gene (SLC12A5) in colorectal cancer | Prof. YU JUN |
| 2016.622 | Elucidating a novel tumor promoting gene Ring Finger Protein 6 in colorectal cancer |
Prof. YU Jun 于君 |
| 2016.675 | Development of novel DNA methylation-based plasma biomarkers for early detection of gastric cancer | Prof. YU Jun |
| 2017.176 | Function of docking protein-1 in immunotherapy of gastric cancer |
Prof. YU Jun 于君 |
| 2008.531 | Clarification of the role of H. pylori infection on the activation of STAT3 through dissecting STAT3 signaling network in gastric cancer | Dr YU Jun |
| 2008.536 | Epstein-Barr Virus and Gastric Cancer: Viral Carcinogenesis through DNA Methylation | Dr. YU Jun |
| 2019.132 | A study of the clinical significance and molecular mechanism of TRIP6 in colorectal cancer invasion and metastasis. |
Prof. YU Jun 于君 |
| 2018.117 | Role of N6-methyladenosine modification in colorectal cancer: functions, mechanisms and implications |
Prof. YU Jun 于君 |
| 2020.024 | Elucidating the role of gut microbial dysbiosis in colorectal cancer |
Prof. YU Jun 于君 |
| 2019.093 | Non-invasive diagnosis of colorectal cancer using microbial markers |
Dr. YU Jun 于君 |
| 2019.073 | Defining the role of RNA N6-methyladenosine writer methyltransferase like 3 (METTL3) in colorectal cancer |
Prof. YU Jun 于君 |
| 2019.425 | Exploiting epitranscriptome dysregulation in colorectal carcinogenesis and metastasis: mechanisms and novel therapeutic approaches |
Prof. YU Jun 于君 |
| 2018.058 | Dissecting the role of SQLE which links aberrant cholesterol mechanism to the induction of Non-alcoholic fatty liver disease |
Prof. YU Jun 于君 |
| 2020.062 | Characterization on the role of RNA Demethylase AlkB Homolog 5 (ALKBH5) in colorectal cancer |
Prof. YU Jun 于君 |
| 2019.617 | Evaluation of SQLE as a novel therapeutic target in non-alcoholic fatty liver disease |
Prof. YU Jun 于君 |
| 2018.463 | Gut microbiota and Hepatocellular carcinoma | Prof. YU Jun |
| 2018.359 | Centre for Gut Microbiome in Cancers |
Prof. YU Jun 于君 |
| 2012.283 | Functional characterization and clinical implication of AMPD1, a novel recurrent mutation gene identified by whole exome sequencing in colon cancer | Dr. YU JUN |
| 2008.182 | Latent-lytic Switch of Epstein-Barr Virus Infection in EBV Associated Gastric Cancer | Dr YU Jun |
| 2013.149 | Genome-wide Identification and Characterization of Genomic Mutations in Non-alcoholic Steatohepatitis-induced Hepatocellular Carcinoma | Dr. YU Jun |
| 2012.123 | The genome-wide characterization of the molecular mechanisms in Epstein-Barr Virus-associated gastric cancer using next-generation sequencing technology | Dr. YU JUN |
| 2013.263 | Elucidating dysbiotic gut microbiota associated with colorectal cancer by metagenomic sequencing | Dr. YU JUN |
| 2010.143 | Functional role and potential clinical application of paired box gene 5 in gastric cancer | Dr. Yu Jun |
| 2011.143 | Functional significance and clinical aplication of Epstein-Barr Virus-driven novel promoter hypermethylated genes (SSTR1, REC8, IL15RA) in gastric cancer | Dr YU JUN |
| 2008.146 | Association of NF-kappaB Super Suppressor (NEKBIA) Polymorphism with Gastric Cancer Risk: A Case-control Study | Dr YU Jun |
| 2013.364 | Functional characterization and clinical implication of SLC12A5, a novel early mutated gene identified by single cell sequencing in colon cancer | Dr. YU Jun |
| 2011.285 | Functional characterization and clinical application of a novel candidate tumor suppressor (antrum mucosal protein-18) in gastric cancer | Dr. YU Jun |
| 2023.114 | RNA m6A去甲基化酶ALKBH5对结直肠癌化疗疗效的影响及作用机制 (Targeting RNA m6A eraser ALKBH5 boosts the efficacy of chemotherapy in colorectal cancer) |
Prof. YU Jun 于君 |
| 2022.203 | Altered gut microbiome composition by appendectomy contributes to colorectal cancer |
Prof. YU Jun 于君 |
| 2021.451 | Developing probiotics into high-efficacy and safe prophylactics and adjuvant therapies for colorectal cancer |
Prof. YU Jun 于君 |
| 2023.022 | RNA N6-Methyladenosine Demethylase AlkB Homolog 5 (ALKBH5) promotes stemness and chemoresistance in colorectal cancer: mechanism and novel therapeutic approaches |
Prof. YU Jun 于君 |
| 2020.685 | Deciphering the role and molecular mechanisms of predominant bacterial pathogens in colorectal cancer pathogenesis and augment therapies |
Prof. YU Jun 于君 |
| 2023.016 | Microbiota in Gastrointestinal Cancers: Mechanistic Investigation and Clinical Applications |
Prof. YU Jun 于君 |
| 2020.684 | RNA Demethylase AlkB Homolog 5 (ALKBH5) drives immune suppression in colorectal cancer via epitranscriptome regulation of AXIN2-WNT-DKK1 axis |
Prof. YU Jun 于君 |
| 2022.026 | RNA N6-Methyladenosine (m6A) Methyltransferase METTL3 facilitates non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLDHCC) via a m6A-cholesterol axis to repress T-cell function |
Prof. YU Jun 于君 |
| 2022.025 | Modulation of antitumor immune response by gut microbiota: characterization, molecular mechanism and translational value |
Prof. YU Jun 于君 |
| 2022.108 | RNA m6A甲基化识别蛋白YTHDF1在调控结直肠癌免疫微环境中的作用及机制研究 (Elucidating the role and mechanism of RNA m6A reader YTHDF1 in regulating the immune microenvironment of colorectal cancer) |
Prof. YU Jun 于君 |
| 2023.017 | Deciphering the role of gut microbiota in modulating antitumor immune response in colorectal cancer: mechanisms and translational value |
Prof. YU Jun 于君 |
Page 8 of 288.